Wugen is an innovative brand that specializes in developing off-the-shelf cellular therapies for cancer. With a focus on optimizing their treatments through evolution, Wugen harnesses the power of NK cells and CAR-T cells to target and eliminate cancer cells. Their therapies cater to patients with solid tumors, acute myeloid leukemia (AML), and T-cell malignancies.

What sets Wugen apart is that their cell therapy products originate from healthy donors and are further enhanced to enhance their anti-cancer properties. Through their cutting-edge research and development, they have established a strong pipeline of convenient, off-the-shelf therapies that are designed to effectively treat cancer patients. With a commitment to scientific excellence, Wugen's team is led by experienced and visionary experts in the field of cancer research.

They have a dedicated Board of Directors and Scientific Advisory Board to guide their endeavors. Wugen's mission is to revolutionize cancer treatment by providing accessible and effective therapies that bring hope to patients. With their groundbreaking advancements and commitment to improving lives, Wugen is at the forefront of the fight against cancer